Cardiovascular Inflammation

Cardiovascular Inflammation

Cardiovascular inflammation is measured rather than felt. It is defined by laboratory markers, principally high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor alpha, and hs-CRP above 2 mg/L is present in roughly 25 percent of US adults. There is no symptom attached to that finding. Its significance lies in what it accompanies: accelerated atherosclerosis and, more specifically, plaque instability, since inflammatory activity within a lesion degrades the fibrous cap that separates its lipid core from the circulation.

The distinction between plaque size and plaque stability is what moved inflammation from the margins of cardiology to its centre. A modestly narrowed but inflamed lesion can rupture and occlude a vessel, while a heavily calcified one may narrow the lumen for years without an event. Inflammatory markers are therefore read as an index of activity rather than of extent.

Inflammation is also a necessary process, not simply a pathological one, which complicates any attempt to suppress it. Reviews of its role across age-related disease have described it as double-edged for exactly this reason: the same cascade that destabilises a plaque is the one that contains infection and repairs tissue ^[1]. This constrains the design of any intervention aimed at the marker rather than at its cause.

Two ingredients are graded against this endpoint here, on 15 studies and 1,200 participants between them. Curcumin holds Grade B on 12 studies and 1,000 participants. Its mechanistic case is well developed, centring on interference with NF-kappa-B signalling and the downstream production of inflammatory cytokines. Its clinical case has a persistent obstacle, bioavailability: curcumin is poorly absorbed, rapidly metabolised and quickly cleared, so formulation differences between trials are large enough to complicate comparison. A review of what the accumulated clinical trials have and have not established addresses that difficulty directly ^[2].

Krill oil holds Grade D on 3 studies and 200 participants. Its EPA and DHA are carried in phospholipid rather than triglyceride form, which has been proposed to alter absorption, but three studies with 200 participants cannot resolve whether that difference is consequential.

Both entries are recorded with a positive direction, which describes the consistency of a small literature rather than the size of any effect.

The listed risk factors point toward the sources rather than the marker. Visceral adiposity is the most quantitatively important, because adipose tissue is an endocrine organ that secretes interleukin-6 and recruits macrophages as it expands. Periodontal disease appears on the list because a chronic bacterial burden at a mucosal surface raises systemic markers measurably. Metabolic syndrome, autoimmune conditions, smoking, sedentary living and poor diet complete it. Each of these acts on hs-CRP more reliably than any ingredient catalogued against it.